PAMU
PDSB icon

Pictet Asset Management (UK)’s PDS Biotechnology PDSB Stock Holding History

Pictet Asset Management (UK)’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-17,786
Closed -$420K – 903
2018
Q1 		$420K Buy
+17,786
New +$4.78M ﹤0.01% 853

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pictet Asset Management (UK)'s PDSB Position: Q2 2018 in Review

Pictet Asset Management (UK) sold out of PDS Biotechnology (PDSB) in Q2 2018, closing a stake of 17,786 shares — an estimated $420K sold.

Pictet Asset Management (UK) first reported a position in PDSB in Q1 2018 and held it in 1 quarter. The position peaked at $420K in Q1 2018. 43 funds tracked by Wall St. Rank hold PDSB as of Q2 2018.

  • Pictet Asset Management (UK) reported no remaining PDS Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Pictet Asset Management (UK) sold 17,786 PDS Biotechnology shares in Q2 2018, an estimated $420K.
  • Pictet Asset Management (UK) first reported a position in PDS Biotechnology in Q1 2018 and held it in 1 quarter.
  • Pictet Asset Management (UK)'s PDS Biotechnology position peaked at $420K in Q1 2018.
  • 43 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2018.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2018, filed 13 Aug 2018.